Agios Pharmaceuticals, Inc. (AGIO)

NASDAQ: AGIO · IEX Real-Time Price · USD
46.61
-1.07 (-2.24%)
At close: Jul 19, 2024, 4:00 PM
46.30
-0.31 (-0.67%)
After-hours: Jul 19, 2024, 5:19 PM EDT
-2.24%
Market Cap 2.65B
Revenue (ttm) 29.40M
Net Income (ttm) -352.62M
Shares Out 56.77M
EPS (ttm) -6.32
PE Ratio n/a
Forward PE 2.47
Dividend n/a
Ex-Dividend Date n/a
Volume 526,904
Open 47.79
Previous Close 47.68
Day's Range 46.54 - 48.35
52-Week Range 19.80 - 49.06
Beta 0.78
Analysts Buy
Price Target 50.67 (+8.71%)
Earnings Date Aug 1, 2024

About AGIO

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2013
Employees 386
Stock Exchange NASDAQ
Ticker Symbol AGIO
Full Company Profile

Financial Performance

In 2023, AGIO's revenue was $26.82 million, an increase of 88.36% compared to the previous year's $14.24 million. Losses were -$352.09 million, 51.9% more than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for AGIO stock is "Buy." The 12-month stock price forecast is $50.67, which is an increase of 8.71% from the latest price.

Price Target
$50.67
(8.71% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Agios to Webcast Conference Call of Second Quarter 2024 Financial Results on August 1, 2024

CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announce...

1 day ago - GlobeNewsWire

Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study

Agios Pharmaceuticals said on Monday its experimental treatment for an inherited blood disorder met the main goal in a late-stage study.

6 weeks ago - Reuters

Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

– Study Achieved the Primary Endpoint; Mitapivat Demonstrated a Statistically Significant Transfusion Reduction Response Compared to Placebo –

6 weeks ago - GlobeNewsWire

Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...

7 weeks ago - GlobeNewsWire

Agios Pharmaceuticals to Present Clinical and Translational Data in Rare Blood Disorders at European Hematology Association 2024 Hybrid Congress

– Data from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia to be Presented in Plenary Session –

2 months ago - GlobeNewsWire

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced...

2 months ago - GlobeNewsWire

Agios Reports Business Highlights and First Quarter 2024 Financial Results

– Topline Data Readout from the Phase 3 ENERGIZE-T Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia now expected in Q2 2024 –

2 months ago - GlobeNewsWire

Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024

CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...

3 months ago - GlobeNewsWire

Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024

CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announc...

4 months ago - GlobeNewsWire

Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024

CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...

5 months ago - GlobeNewsWire

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

– Announced Positive Results from the Phase 3 ENERGIZE Study of Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia – – Presented Positive Results from Phase 2 Portion of the...

5 months ago - GlobeNewsWire

Agios to Webcast Conference Call of Fourth Quarter and Year End 2023 Financial Results on February 15, 2024

CAMBRIDGE, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...

6 months ago - GlobeNewsWire

Agios Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

– Industry-leading PK Activator Franchise Has Demonstrated Clinical Efficacy in Four Hematological Diseases, Including New Positive Phase 3 Data in Non-Transfusion-Dependent Thalassemia –

6 months ago - GlobeNewsWire

Agios Pharma's stock soars 19.6% on news of positive results in trial of treatment for rare blood disorder

Agios Pharmaceuticals Inc.'s stock AGIO, +2.51% soared 19.6% early Wednesday, after the biotech announced positive results from a Phase 3 trial of a treatment for a rare blood disorder. The trial dubb...

7 months ago - Market Watch

Agios' blood disorder drug meets goals of late-stage study

Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder.

7 months ago - Reuters

Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia

–Mitapivat Demonstrated a Statistically Significant Increase in Hemoglobin Response Rate Compared to Placebo – – Statistical Significance Also Achieved for Key Secondary Endpoints of  Change From Base...

7 months ago - GlobeNewsWire

Agios to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...

7 months ago - GlobeNewsWire

Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition

– Treatment with Mitapivat Demonstrated Statistically Significant Improvement in Hemoglobin Response Compared to Placebo – – Improvements Observed in Annualized Rates of Sickle Cell Pain Crises, Marke...

7 months ago - GlobeNewsWire

Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence; One Study Patient Achieved Hemoglobin Response Endpoint –

8 months ago - GlobeNewsWire

Agios Pharmaceuticals to Present Broad Set of Clinical and Translational Data in Rare Blood Disorders at 65th ASH Annual Meeting and Exposition

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support Advancem...

9 months ago - GlobeNewsWire

Agios Reports Business Highlights and Third Quarter 2023 Financial Results

– First Patient Dosed in Phase 3 Portion of the RISE UP Pivotal Study of Mitapivat in  Sickle Cell Disease –

9 months ago - GlobeNewsWire

Agios to Webcast Conference Call of Third Quarter 2023 Financial Results on Nov. 2, 2023

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced the...

9 months ago - GlobeNewsWire

Agios to Present at the Morgan Stanley Global Healthcare Conference on September 12, 2023

CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced tha...

11 months ago - GlobeNewsWire

Agios Reports Business Highlights and Second Quarter 2023 Financial Results

CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported busi...

1 year ago - GlobeNewsWire

Agios Announces Exclusive Worldwide License Agreement for Novel siRNA for the Potential Treatment of Polycythemia Vera

– Preclinical siRNA Targeting TMPRSS6 is a Potential Disease-Modifying Treatment for Polycythemia Vera – – Agreement Combines Agios' Scientific Expertise and Capabilities in Rare Hematologic Diseases ...

1 year ago - GlobeNewsWire